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Abstract Many children with hypertension, particularly
those with new-onset hypertension related to glomerulo-
nephritis, organ transplantation, or other forms of sec-
ondary hypertension, require treatment with a short-
acting antihypertensive in order to quickly achieve blood
pressure (BP) control. We administered isradipine, a
short-acting, second-generation calcium antagonist, to 72
such children. Retrospective data collection was under-
taken to determine the effects of isradipine treatment.
The mean age of children treated with isradipine was
74±55 months (mean±SD). Nearly all of these children
had secondary hypertension and were initially treated as
hospital inpatients for newly diagnosed hypertension.
Mean isradipine dose was 0.36±0.17 mg/kg per day, with
no significant variation in dose according to patient age.
Isradipine was administered three times per day in most
instances, but 21% of the time it was administered four
times per day. An extemporaneous isradipine suspension
was used in 62% of treatment courses. BP control was
achieved with isradipine alone in 38 children; the re-
mainder received isradipine in combination with addi-
tional antihypertensives. Comparison of pre-treatment
BP with BP obtained 8±9 days later demonstrated a sig-
nificant BP reduction with isradipine treatment, with a
mean reduction of 14±13 mmHg for systolic BP and
13±15 mmHg for diastolic BP. There was no effect of 
isradipine treatment on heart rate. Adverse effects oc-
curred in 9.5% of treatment courses, and included head-
ache, flushing, dizziness, and tachycardia. We conclude
that isradipine successfully lowers BP in hypertensive
children with secondary forms of hypertension. Use of
isradipine suspension allows infants and young children
to be treated as readily as older children.
Keywords Clinical trial · Calcium channel blocker · 
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Introduction
Treatment of hypertensive children has been hampered
by the limited information available regarding efficacy
and safety of antihypertensive medications in children
[1]. This problem is perhaps most significant for more
recently introduced calcium antagonists and angiotensin
converting enzyme inhibitors, which have been recom-
mended as first-line agents for use in hypertensive 
children [2]. Additionally, few antihypertensive agents
are available in formulations suitable for administration
to infants and toddlers, which means that suspensions
must be compounded locally, many of which may not be
uniform in potency or stable for long periods of time 
[1, 3].
Treatment of children with hypertension of acute 
onset (such as that caused by acute glomerulonephritis,
organ transplantation, or other conditions) is further
compounded by the lack of an agent that could achieve
blood pressure (BP) control relatively rapidly, within a
few days at most, with a low incidence of adverse ef-
fects. Ease of administration and of titration would be
additional desirable attributes of such an agent. Many
currently available antihypertensive agents, however, do
not fulfill these criteria. Vasodilators such as hydralazine
and minoxidil have significant adverse effects or cannot
be compounded into stable suspensions [4, 5]. Beta-
adrenergic antagonists (i.e., propranolol or labetalol)
may cause bradycardia or bronchospasm [6]. First-gener-
ation calcium antagonists either have adverse cardiovas-
cular effects (verapamil) or are difficult to administer
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(nifedipine), whereas the third-generation calcium antag-
onist amlodipine may not achieve therapeutic effect rap-
idly enough [7]. Angiotensin converting enzyme inhibi-
tors may be contraindicated because of transient renal
dysfunction.
Isradipine, a second-generation dihydropyridine calci-
um antagonist, has several characteristics that would ap-
pear to make it an ideal agent for treatment of hyperten-
sion of acute onset. It has high affinity for L-type calci-
um channels located in vascular smooth muscle, and 
little effect on myocardial calcium channels, leading to a
fairly specific and potent antihypertensive effect [8]. On-
set of action is rapid, within 30 min of oral administra-
tion, a property that has led some investigators to utilize
isradipine as a treatment for urgent hypertension [9].
When used in chronic treatment of hypertension in
adults, isradipine is generally well tolerated, with a fa-
vorable adverse effect profile compared with the first-
generation calcium antagonist nifedipine [10, 11]. Final-
ly, and perhaps most importantly as far as treatment of
children is concerned, isradipine may be easily com-
pounded into a stable extemporaneous suspension [12].
For these reasons, isradipine was applied to the treatment
of hypertensive children at the University of Michigan in
1994. Our experience with the use of this agent in chil-
dren is summarized in this report.
Materials and methods
Patient eligibility
Patients were eligible for inclusion in this study if they had received
treatment for hypertension (as defined below) with isradipine be-
tween July 1995 and May 2000. Pediatric nephrology fellows and
attending physicians identified potential patients to the principal in-
vestigator, who then reviewed their medical records to confirm eli-
gibility. The investigators’ database was cross-referenced with dis-
pensing records from the medical center’s outpatient pharmacy in
order to identify additional children that had been treated with is-
radipine at the institution during the study period. All children so
identified were then added to the investigators’ database.
Data collection
Data for this retrospective study were collected by review of pa-
tients’ medical records under the auspices of an ongoing antihy-
pertensive database maintained by the Division of Pediatric Neph-
rology. The University of Michigan Institutional Review Board for
Medical Research granted approval for maintenance of this dat-
abase on an annual basis.
Data were collected utilizing a standardized collection form as
previously described [13]. All data collection was performed by a
single individual (S.W.) who had been trained by the principal in-
vestigator (J.F.). Quality control of the data collection was main-
tained by ongoing review of the completed data collection forms
by the principal investigator.
Demographic information collected included patient’s age,
weight, underlying diagnosis, presence or absence of hypertension
prior to isradipine use, and treatment with other antihypertensive
medications prior to use of isradipine. Vital signs, including sys-
tolic BP, diastolic BP, and heart rate were recorded from inpatient
nursing flow sheets and outpatient clinic records. Isradipine dose
and formulation, use of concomitant antihypertensive medications,
and adverse effects reported by patients were also recorded.
To determine the effects of isradipine treatment in hospitalized
patients, the patients’ BP and heart rate during the 24 h prior to the
use of isradipine were recorded, followed by their BP, heart rate,
and isradipine dose on the day of discharge from the hospital. For
outpatients, clinic BP and heart rates were recorded for the clinic
visit immediately preceding the initial use of isradipine, followed
by the patients’ BP, heart rates, and isradipine dose on the first fol-
low-up visit.
BP measurement and definitions
BP in all patients was measured by either the hospital inpatient
nursing staff or outpatient clinic staff using automated oscillomet-
ric BP monitors (Dynamap, Critikon, Tampa, Fla., USA). In hos-
pitalized patients, BP was measured every 1–4 h as warranted by
the patient’s clinical condition. Clinic BP was measured in the
right arm with the child seated; choice of extremity and patient po-
sition in hospitalized patients varied according to their clinical
condition.
Hypertension in all patients was defined as a systolic and/or 
diastolic BP in excess of the 95th percentile for that child’s age,
gender, and height [2]. Target BP for all patients treated with 
isradipine was set at the 90th percentile [14].
Isradipine treatment
Children eligible for treatment with isradipine included any child
with hypertension who could be treated with an oral agent. Isradi-
pine was generally not used for the treatment of urgent hyperten-
sion; at our center, such children were typically treated with intra-
venous labetalol as previously described [7]. However, children
receiving ongoing chronic treatment with isradipine could receive
additional doses for acute BP elevations if necessary.
Isradipine was started at a dose of 0.05–0.1 mg/kg per dose 
every 8 h and adjusted as necessary to reduce the patient’s BP,
until the target BP was reached. Frequency of dosing was in-
creased to every 6 h if the patient’s BP frequently exceeded the
target range more than 1 h before the next scheduled isradipine
dose, or if additional doses were frequently being administered as
described above. If BP control was not achieved with isradipine
alone, additional antihypertensive agents were added as neces-
sary.
Isradipine was administered either as commercially available
2.5- or 5-mg immediate-release capsules (DynaCirc, Novartis
Pharmaceuticals, East Hanover, N.J., USA) or as a 1.0 mg/ml ex-
temporaneous suspension compounded by the C.S. Mott Chil-
dren’s Hospital pharmacy [12]. Occasional patients who were re-
ceiving a total daily dose of isradipine of 5 or 10 mg were
switched to commercially available extended-release tablets 
(DynaCirc CR, Novartis Pharmaceuticals) administered once or
twice daily.
Data analysis
Database software used included the Medlog clinical data manage-
ment system (Information Analysis Corporation, Incline Village,
Nev., USA) and Excel 97 (Microsoft Corporation, Redmond,
Wash., USA). Further data analysis was performed utilizing SPSS
for Windows 10.0.5 (SPSS, Chicago, Ill., USA).
Except where otherwise noted, data included in this report are
expressed as mean±standard deviation, or as percentages. Statisti-
cal tests utilized included two-tailed, paired and unpaired t-tests to
examine differences in group means for normally distributed vari-
ables and the Mann-Whitney and Wilcoxon signed ranks tests for
non-normally distributed variables. The Chi-square test or Fisher’s
exact test was used to examine the differences in proportions be-
tween groups. Linear regression analysis was performed to exam-
ine the relationship between variables. Statistical significance for




A total of 80 children were identified as having been
treated with isradipine at the University of Michigan be-
tween July 1995 and May 2000. However, BP data were
missing for 4 patients, and were incomplete for another 
4 patients. Two additional patients received isradipine on
two separate occasions (before and after renal transplan-
tation in both instances), leaving 72 patients and 74
treatment courses that are analyzed in this report. BP and
other data from the 4 treatment courses in the 2 children
who received isradipine twice were treated as coming
from 4 separate patients for purposes of analysis.
Mean patient age was 74±55 months (6.2±4.6 years),
with a range of 1 week to 16.8 years. Of the 72 patients,
70 (97.2%) had secondary hypertension. Underlying 
diagnoses for the 72 treatment courses in children 
with secondary hypertension included glomerulonephri-
tis (18 patients), renal transplant (16 patients), liver
transplant (16 patients), reflux nephropathy (5 patients),
steroid-induced (5 patients), renovascular (3 patients),
and other (9 patients). Hypertension in the solid organ
transplant recipients was typically related to volume
overload, the effects of immunosuppressive medications
(corticosteroids and calcineurin inhibitors), pre-trans-
plant hypertension, or a combination of these factors.
Of the 74 isradipine treatment courses, 68 (91.9%)
were begun during inpatient hospitalizations; the remain-
ing 6 were begun in the outpatient department. In 46 of
74 treatment courses (62%), isradipine was the initial an-
tihypertensive agent utilized; in the remaining 28 instanc-
es, the patients were being treated with other agents and
had isradipine added to their antihypertensive regimen.
In 38 of the 74 treatment courses (51.4%), target BP
was reached with isradipine alone. In 28 instances
(37.8%) one additional medication was required, and in 8
(10.8%) two additional medications were needed. Supple-
mental medications utilized included diuretics (20 pa-
tients), beta-adrenergic antagonists (10 patients), direct
vasodilators (minoxidil or hydralazine, 7 patients), angio-
tensin converting enzyme inhibitors (5 patients), and
transdermal clonidine (2 patients). Pre-treatment charac-
teristics of the children requiring additional medications
compared with those who did not require additional med-
ications are listed in Table 1. Patient age, weight, and dia-
stolic BP were similar in the two groups, where-as initial
systolic BP tended to be higher in the group that required
additional medications. There was no unusual distribution
of diagnoses between the two groups (Table 1).
In 46 of the 74 treatment courses (62%), a locally
compounded isradipine suspension was used. As would
be expected, these children were significantly younger
than children who received isradipine capsules or ex-
tended-release tablets (mean age of patients receiving
suspension was 39±28 months vs. 132±36 months for
those receiving capsules or tablets, P<0.0001).
Isradipine dosing
The mean isradipine dose received by all patients com-
bined once target BP was reached was 0.36±0.17 mg/kg
per day (range 0.07–0.9 mg/kg per day). Doses received
by patients in specific age, diagnosis, and dosing groups
are summarized in Table 2. Linear regression analysis re-
Table 1 Comparison of pa-
tients receiving isradipine
monotherapy with those receiv-
ing combination therapy (BP
blood pressure)
Characteristic Isradipine monotherapya Combination therapyb P
(n=38) (n=36)
Age (months)c 78±61 70±50 NS*
Weight (kg)c 25±18 22±15 NS*
Initial BP (mmHg)c
Systolic 129±12 135±14 0.06**
Diastolic 80±11 83±13 0.22**
Glomerulonephritis 12 (32%) 6 (17%) NS***
Solid organ transplant 15 (40%) 17 (47%) NS***
* Mann-Whitney test, **two-tailed, unpaired t-test, ***Chi-square test
a Treatment courses in which BP control was achieved by isradipine alone
b Treatment courses in which additional agents were needed to achieve BP control
c Mean±standard deviation.
Table 2 Isradipine dose received according to age, diagnosis, or
dosing regimen (t.i.d. three times a day, q.i.d. four times a day)
Group n Dose received
(mg/kg per day)
All treatment courses combined 74 0.36±0.17
Age groups
0–1 year 9 0.27±0.11
1–6 years 32 0.38±0.20
6–12 years 21 0.39±0.16
>12 years 12 0.28±0.16
Solid organ transplant 32 0.34±0.13
Glomerulonephritis 18 0.38±0.16
Isradipine monotherapy 38 0.31±0.12*
Combination therapy 36 0.40±0.21*
t.i.d. dosing 45 0.33±0.16**
q.i.d. dosing 20 0.45±0.18**
*P=0.04 for comparison of monotherapy with combination thera-
py (two-tailed t-test), **P=0.01 for comparison of t.i.d. dosing
with q.i.d. dosing (two-tailed t-test)
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vealed no significant association between patient age and
isradipine dose. Patients whose BP was controlled with
isradipine alone received a significantly lower dose than
those in whom BP control required isradipine in combi-
nation with other agents (Table 2). Dose was similar in
children who received isradipine as a suspension com-
pared with those who received capsules or tablets
(0.36±0.18 mg/kg per day vs. 0.34±16 mg/kg per day,
P=NS).
Isradipine was administered three times daily in 45
instances (60.8%), four times daily in 20 instances
(27%), and once or twice daily in the remaining 9 in-
stances (12.2%). The mean isradipine dose when it was
administered four times daily was significantly higher
than when it was given three times daily (Table 2). There
was no relationship seen between patient age and dosing
frequency. However, children who received isradipine
suspension tended to be more likely to receive it more
than twice a day than those who received isradipine cap-
sules: 93% of suspension recipients were dosed three or
four times daily versus 79% of capsule recipients
(P=0.07, Fisher’s exact test).
Effects of isradipine treatment
BP data for all 74 treatment courses and for specific age
groups are summarized in Table 3. The mean time between
the baseline (pre-isradipine treatment) and follow-up BP
was 8±9 days (range 1–42 days). Isradipine treatment pro-
duced a significant reduction in both systolic and diastolic
BP in all age groups. There was no significant change in
heart rate with isradipine treatment, except in infants
<1 year old, in whom heart rate decreased from 148 to 132
beats per min (P=0.04, two-tailed paired t-test).
For further assessment of the effects of isradipine
treatment, the BP responses in the 38 treatment courses
when BP control was achieved by isradipine alone were
examined separately. Results are summarized in Table 4.
In general, for almost every age group, there was a sig-
nificant reduction in BP following isradipine treatment.
There was no significant change in heart rate with isradi-
pine treatment for any age group (data not shown).
To determine whether there was a dose-response rela-
tionship between isradipine dose and the change in BP,
linear regression analysis was performed. In order to
eliminate the effects of other antihypertensive medica-
tions, this analysis was restricted to the 38 treatment
courses when isradipine was used as monotherapy. No
significant relationship was demonstrated between isradi-
pine dose (in mg/kg per day) and change in systolic or di-
astolic BP, expressed either as absolute change in mmHg
(baseline BP minus treatment BP), or as percentage
change [(baseline BP minus treatment BP)/baseline BP].
Adverse effects
Adverse effects attributed to isradipine treatment oc-
curred in 7 of 74 treatment courses (9.5%) during the pe-
Table 3 BP reduction with 
isradipine treatmenta Group n BP prior to BP during Mean change P*
isradipine treatment isradipine treatment in BP
Age 0–1 years 9 120±12 100±15 21±12 0.001
77±15 56±12 21±15 0.003
Age 1–6 years 32 131±9 116±9 15±12 <0.0001
80±12 69±8 12±15 <0.0001
Age 7–12 years 21 133±14 122±10 11±13 0.001
81±9 70±10 12±12 <0.0001
Age >12 years 12 141±17 127±10 13±14 0.01
88±14 76+9 12±18 0.04
All treatment courses 74 132±13 117±13 14±13 <0.0001
combined 81±12 68±11 13±15 <0.0001
* Two-tailed, paired t-test
a For each row, the upper value
is systolic BP (mean±SD) and
the lower value is diastolic BP
(all in mmHg)
Table 4 BP reduction with 
isradipine monotherapya Group n BP prior to BP during Mean change P*
isradipine treatment isradipine treatment in BP
Age 0–1 years 6 117±13 97±17 21±11 0.006
77±13 58±15 19±12 0.01
Age 1–6 years 14 132±10 117±8 16±13 0.001
79±13 70±10 9±18 0.08
Age 7–12 years 10 127±11 120±10 7±11 0.07
79±8 71±8 8±11 0.04
Age >12 years 8 134±13 124±10 10±11 0.03
84±8 75+8 9±6 0.003
All treatment courses 38 129±12 116±14 13±12 <0.0001
combined 80±11 69±11 10±13 <0.0001
* Two-tailed, paired t-test
a For each row, the upper value
is systolic BP (mean±SD) and
the lower value is diastolic BP
(all in mmHg)
riod of follow-up in this study, for a rate of 0.35 adverse
events per patient-month of treatment. Adverse effects
reported included headache (2 patients), flushing (2 pa-
tients), dizziness (1 patient), tachycardia (1 patient), and
unspecified (1 patient). No patient reported more than
one adverse effect. There was no difference in the inci-
dence of adverse effects between children treated with
isradipine alone compared with those treated with isradi-
pine plus additional medications, and no difference in
the dose of isradipine received between children with
and without adverse effects.
Discussion
In this single-center study, the second-generation di-
hydropyridine calcium antagonist isradipine was adminis-
tered to a relatively large group of hypertensive children
that are typical of patients with hypertension seen at pedi-
atric nephrology centers. In these children, nearly all of
whom had secondary hypertension and were being treat-
ed as hospital inpatients, isradipine significantly lowered
both systolic and diastolic BP, an effect that was present
no matter whether isradipine was being administered
alone or in combination with other antihypertensive
agents. There was no significant effect of isradipine on
heart rate, except in infants <1 year of age who received
isradipine in combination with other agents. The lack of
an effect on heart rate in patients of all ages receiving is-
radipine monotherapy suggests that this change may have
been related to the additional antihypertensives received
by some of those infants. Use of a locally compounded
isradipine suspension facilitated treatment of children as
young as 1 week of age. Although the incidence of ad-
verse effects related to isradipine treatment was not insig-
nificant, it was smaller than that reported by other investi-
gators [15] and compared favorably with our experience
with the calcium antagonist amlodipine [13].
Several findings in this study merit further discussion.
As has been found by other investigators [15, 16], the
doses of isradipine administered to the children in this
study were significantly greater than doses typically used
in adults. Although this has also been reported for sever-
al other calcium antagonists, most notably amlodipine
[13], because of the retrospective, uncontrolled design of
this study it is difficult to know whether children truly
require greater doses than adults or whether this finding
simply represents the prescribing practices at our center.
It may also be related to the fact that most of the children
received isradipine in suspension form. Although the
suspension remains stable after compounding [12], there
may be differences in bioavailability of the suspension
compared with the commercially available formulations
that may reduce the magnitude of the antihypertensive
effect of the suspension.
Another important finding was that most of the chil-
dren in this study seemed to require administration of is-
radipine three or four times daily to maintain stable BP.
While this is greater than the recommended frequency
for adults of two times per day, it is consistent with the
relatively short elimination half-life of isradipine of as
little as 6 h [10]. It may also be related to the extensive
first-pass hepatic metabolism of isradipine [10] and the
possibility that children may clear this drug more rapidly
than adults due to their proportionately greater hepatic
mass. Clearly, a formal pharmacokinetic study would be
necessary to settle this issue.
Despite the wide range of doses of isradipine received
by the patients in this study, and despite the fact that
many children received proportionately higher doses
than those recommended for adults, we were unable to
demonstrate a dose-response relationship between the
dose of isradipine and the magnitude of BP reduction.
This is most likely a function of the retrospective study
design and also of the relatively small number of patients
included compared with clinical trials of other antihyper-
tensives. This question, as well as the pharmacokinetic
issues, could be answered by a multi-center prospective
trial similar to those that have been conducted for other
antihypertensives under the auspices of the Food and
Drug Modernization Act of 1997 [17].
Pediatric use of isradipine has previously been reported
[15, 16, 18]. Johnson et al. [16] studied the effects of is-
radipine in the management of 53 hospitalized children
with hypertension, and found that isradipine produced a
mean reduction in BP of 12%±13% for systolic pressure
and 17%±20% for diastolic pressure. Doses received were
much higher than those reported effective in adults, espe-
cially in children with renal disease. No data were report-
ed regarding the incidence of adverse effects. Similarly,
Strauser et al. [18] reported that isradipine effectively low-
ered BP in 10 of 12 children, most of whom had renal
causes of hypertension. No information was included in
their report regarding the magnitude of BP reduction pro-
duced by isradipine, nor the incidence of adverse effects.
Limitations of this study have been alluded to above
and include the retrospective design, lack of a control
group, and possible selection bias. However, it should be
stressed that the relatively large number of children includ-
ed compared with other single-center studies of antihyper-
tensive agents in children makes it likely that our conclu-
sions regarding isradipine in this patient population are
correct. In addition, we believe that the efforts that were
made to identify children treated with isradipine beyond
those with which the investigators were personally familiar
makes it unlikely that the study findings are significantly
affected by selection bias. Finally, we should point out that
since most of the children in this study had secondary hy-
pertension, we cannot draw any conclusions about the use
of isradipine in children with primary hypertension.
The ideal agent for treatment of children with hyper-
tension remains unknown. We believe that isradipine
represents a useful option, particularly in children like
those in this report who have secondary hypertension re-
quiring prompt treatment. We are hopeful that a prospec-
tive, randomized controlled study will be performed to
more fully evaluate the role of isradipine in the manage-
ment of pediatric hypertension.
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